Overview

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Status:
Completed
Trial end date:
2013-07-17
Target enrollment:
Participant gender:
Summary
This study will evaluate safety, tolerability and effects on central diastolic blood pressure (cDBP) of MK-8892 given as single oral doses in healthy male participants (Panel A and B) and in male participants with mild-to-moderate hypertension (Panel C).
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.